Research programme: epigenetic modulators - Oryzon

Drug Profile

Research programme: epigenetic modulators - Oryzon

Alternative Names: LSD1 inhibitors - Oryzon; OG S1335; ORY 3001

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oryzon
  • Class Anti-inflammatories; Antianaemics; Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Sickle cell anaemia; Unspecified
  • Research Autoimmune disorders; Cancer; Inflammation
  • No development reported Viral infections

Most Recent Events

  • 09 Dec 2017 Preclinical trials in Sickle cell anaemia in Spain (PO) before December 2017
  • 09 Dec 2017 Pharmacodynamics data from a preclinical study in Sickle cell anaemia presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 04 Nov 2017 No recent reports of development identified for research development in Viral-infections in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top